foscarbidopa
Small moleculeapprovedOrphan Drug FDA
Approved
Oct 16, 2024
Clinical trial activity
7 trials · 1 clinical orgs · 1 marketing orgs
Phase 1
3
Phase 2
4
Phase 3
4
Phase 4
0
Earliest trial started May 24, 2017 (NCT03033498)
Timeline
Indications
Approved for
Studied for
Mechanism of action
- Dopamine receptorAGONIST
Dopamine receptor agonist
- DOPA decarboxylaseINHIBITOR
DOPA decarboxylase inhibitor
Combination products
vyalev
with foslevodopa
Approval history
- approvedOct 16, 2024
Chemistry & pharmacology
Loading structure…
SMILES
C[C@@](Cc1ccc(OP(=O)(O)O)c(O)c1)(NN)C(=O)O- Mol. weight
- 306.21 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Parenteral
- Availability
- Prescription Only
Oral
No
Parenteral
Yes
Topical
No
Prodrug
Sources
- ChEMBLCHEMBL4802240 ↗
Also known as
- abbv-951
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05094050 | Phase 1 | Nov 21, 2021 | AbbVie |
| NCT04750226 | Phase 3 | Feb 18, 2021 | AbbVie |
| NCT04380142 | Phase 3 | Jul 13, 2020 | AbbVie |
| NCT04379050 | Phase 3 | Jun 4, 2020 | AbbVie |
| NCT03781167 | Phase 3 | Apr 29, 2019 | AbbVie |
| NCT03374917 | Phase 1 | Apr 18, 2018 | AbbVie |
| NCT03033498 | Phase 1 | May 24, 2017 | AbbVie |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AbbVie | For profit | 7 | 7 | 2 | 2017 |
1 organizations
Page 1 / 1
Marketing (1)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| AbbVie | For profit | NDA | Oct 16, 2024 |